Pharmaceutical company UNIMED continues its positive performance in 2025, reporting a **Q1 revenue of 33.3 million dinars, marking a 2% increase compared to the 32.8 million dinars recorded during the same period in 2024.
This growth was driven by a 17% surge in hospital market sales and a 5% increase in pharmacy revenue, confirming strong market penetration of UNIMED products in retail pharmacies.
In terms of production, the company manufactured 43,113,852 units (ampoules, vials, syringes, and bags) during the first three months of 2025, demonstrating its robust industrial capacity to meet growing market demand.
With regard to investment, UNMED allocated 272,000 dinars to tangible and intangible projects in Q1, reinforcing industrial capabilities and innovation.
The company’s long-term debt stood at 22.6 million dinars (+13%) as of March 31, 2025, while its short-term debt totaled 25.6 million dinars (+2%).
